Back to results
US 12,760,089 B2Granted
SARS-CoV-2 nucleocapsid antibodies
AssigneeRoche Diagnostics Operations, Inc.
InventorsMichael Gerg, Ute Jucknischke, Ulrike Kurtkaya, Thomas Mock, Michael Schraeml, Sandrine Carolina Stiegler
Life of this patent
Estimating the term…
Abstract
The present invention relates to monoclonal antibodies binding to the nucleocapsid protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, as well as methods of detecting SARS-CoV-2 virus in a sample comprising using said antibodies.
Claims17
An isolated monoclonal antibody or antigen-binding fragment thereof that binds to the nucleocapsid protein of SARS-CoV-2 virus
- a) with an association rate constant (ka) of more than 1.0E+05 M−1s−1, as determined by surface plasmon resonance,
- and/or
- b) with a dissociation rate constant (kd) of less than 5.0E−04 s−1, as determined by surface plasmon resonance,
- and/or
- c) with a half-life time of t/2diss of 15 minutes or more, as determined by surface plasmon resonance,
- and/or
- d) with a 1:1 or 1:2 stoichiometry,
- wherein the antibody or antigen-binding fragment comprises:
- (i) CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 according to SEQ ID NO:
- 1, 2, 3, 4, 5, and 6, respectively;
- (ii) CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 according to SEQ ID NO:
- 17, 18, 19, 20, 21, and 22, respectively;
- or
- (iii) CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 according to SEQ ID NO:
- 33, 34, 35, 36, 37, and 38, respectively.
12 more elements
Dependencies are inferred from the claim text.